Abstract 140P
Background
The high recurrence rate after surgical resection remains a big challenge for long-term survival of HCC patients. In order to improve the R0 resection rate, reduce distant metastasis, and lower postoperative recurrence, there is a growing exploration of perioperative treatment. This study aimed to evaluate the efficacy and safety of combining tislelizumab with Lenvatinib and TACE as neoadjuvant therapy in resectable CNLC IIa-IIb HCC patients.
Methods
This study (ClinicalTrials.gov NCT06003673) enrolled patients with primary resectable HCC of CNLC IIa-IIb who had not received prior systemic therapy. For CNLC IIa patients must meet one of the following criteria: unclear tumor boundaries, proximity to blood vessels, or suspicious residual margins. TACE will be performed once only on Day 1. Tislelizumab (200 mg, IV, Q3W) and lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily was initiated on Day1. All patients undergo 2 cycles of neoadjuvant therapy. Patients will undergo surgical resection within 2-4 weeks after neoadjuvant treatment depends on the investigators’ evaluation. Primary endpoint was relapse-free survival (RFS). Secondary endpoints were objective response rate (ORR) by RECIST v1.1, Pathological Complete Response Rate (pCR), Major pathological reactions (MPR), R0 resection rates, overall survival (OS), and adverse events (AE).
Results
Between July 2023 and August 2024, 23 patients were enrolled. As of September 29, 2024, after a median follow-up of 9.4 months. All patients received neoadjuvant, and 19 patients underwent successful R0 resection, 7 patients (7/19,36.9%) achieved complete pathological response, 10 patients (10/19, 52.6%) achieved major pathological reaction (necrosis > 90%). The median age was 59 years old,all Child-Pugh A(100%), ECOG PS 0(100%), mostly males (82.6%), HBV infection (76.2%), BCLC B(100%) and CNLC IIa (63.6%). No grade 4 or 5 TRAE were observed. Median RFS and overall survival were not reached.
Conclusions
Lenvatinib, tislelizumab, and TACE were safe and showed promising efficacy as a neoadjuvant therapy for resectable HCC of CNLC IIa-IIb . Further follow up will continue.
Clinical trial identification
NCT06003673.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract